Summary:
This study is a phase 3 study. A phase 3 study is the third and last pre-approval round of testing of a study treatment conducted on large populations subjects. The goal of this study is to see if a treatment called fezolinetant is both effective and safe as a treatment for moderate to severe hot flashes associated with menopause. Fezolinetant is not an approved product. Past studies with Fezolinetant have been done previously in women going through menopause. The information collected in this study is necessary to find out whether the treatment tested is effective and safe.
Qualified Participants Must:
• Be at least 40 years of age
•
Have not experienced a mentrual cycle for at least 6 months
•
Must not be currently taking any hormonal treatments for hot flashes
Qualified Participants May Receive:
- Compensation for time and travel expenses
- Laboratory testing such as blood work and EKG
- Physical performed by a board certified physician